Correlation between Inflammation and Fibrinolysis in Hypertensive Centrally Obese Subjects: A Study on C-Reactive Protein, Plasminogen Activator Inhibitor-1 and Thrombin Activatable Fibrinolysis Inhibitor

Yati Sumiyati, Syakib Bakri, Mansyur Arif


BACKGROUND: Hypertension and central obesity are risk factors of cardiovascular disease. Epidemiology studies have shown that these two conditions are closely linked and often occur simultaneously. Inflammation is an underlying pathomechanism in hypertension and obesity. Vascular inflammation is related to coagulation pathway, whereby high level of inflammation increases the risk of atherothrombosis event. The aim of this study was to investigate the correlation between inflammation and fibrinolysis in hypertensive centrally obese subjects compared with hypertensive non obese sbjects.

METHODS: This was a cross sectional study conducted in October 2009-June 2010 involving 53 eligible subjects according to the following criteria: men or women aged 30-65 years, had neither diabetes (FPG <126 mg/dL and or OGTT <200 mg/dL) nor CKD (eGFR ≥60 mL/minutes). All subjects were not in an acute inflammation state, had no unspecific infection (hs-CRP ≤10 mg/L), or taking anti-inflammation or anti-hypertensive medication.

RESULTS: In this study we found that the levels of hs-CRP (2.636 mg/L vs 1.024 mg/L, p=0.007), PAI-1 (43.58 ng/mL vs. 28.43 ng/mL, p=0.089) and TAFI (12.73 ng/mL vs. 12.19 ng/mL, p=0.479) were respectively higher in hypertensive subjects with central obesity than in hypertensive subjects with no central obesity. In hypertensive centrally obese subjects there was significant positive correlation between hs-CRP and PAI-1 (r=0.491, p=0.001) and TAFI (r=0.312, p=0.0390, meanwhile in hypertensive non-obese subjects significant correlation was found only between hs-CRP and TAFI (r=0.929, p=0.003).

CONCLUSIONS: Obesity in hypertensive subjects has higher inflammation state that is correlated with fibrinolysis disruption.

KEYWORDS: hypertensive, obesity, hs-CRP, PAI-1, TAFI

Full Text:



Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of The Joint National Committee On Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206-52, CrossRef.

Org E, Veldre G, Viigimaa M, Juhanson P, Putku M, Rosenberg M, et al. HYPEST study: profile of hypertensive patients in Estonia. BMC Cardiovascular Disorders. 2011; 11: 55, CrossRef.

Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension. J Hypertens. 2001; 19: 857-66, CrossRef.

Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006; 47: 1093-100, CrossRef.

Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas J, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180-9, CrossRef.

Wellen KE, Hotamisligil GS. Inflammation, stress and diabetes. J Clin Invest. 2005; 115: 1111-9, CrossRef.

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germanò G, et al. 2007 guidelines for the management of arterial hypertension: The task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007; 28; 1462-536, CrossRef.

Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2004; 61: 122-31, CrossRef.

Tedgui A. The role of inflammation in atherothrombosis: implications for clinical practice. Vasc Med 2005; 10: 45-53, CrossRef.

Verma S, Buchanan MR. and Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003; 108: 2054-9, CrossRef.

Grant PJ, Ajjan R. Coagulation and atherothrombotic disease. Atherosclerosis. 2006; 186: 240-59, CrossRef.

Bouma BN, Meijers JCM. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost. 2003; 1: 1566-74, CrossRef.

Gutierrez-Missin A, Sanchez-Santos MT, Banegas JR, Zunzunegui MV, Castell MV, Otero A. Prevalence and incidence of hypertension in a population cohort of people aged 65 years or older in spain. J Hypertens 2011; 29: 1863-70, CrossRef.

Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J 2008; 7: 1-10, CrossRef.

Engstrom G. Inflammation, obesity and risk of hypertension: shared pathways or independent risk factors? J Hum Hypertens 2011; 25: 71-2, CrossRef.

Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: Results from the MONICA/KORA Augsburg cohort study, 1984-1998. Clin Chem. 2008; 54: 335-42, CrossRef.

Den Engelsen C, Koekkoek PS, Gorter KJ, van den Donk M, Salome PL, Rutten GE. High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis. Cardiovasc Diabetol. 2012; 11: 1-25, CrossRef.

Małyszko J, Tymcio J. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension. Polskie Archiwum Medycyny Wewnętrznej. 2008; 118: 36-40, PMID.

Samocha-Bonet D, Justo D, Rogowski O, Saar N, Abu-Abeid S, Shenkerman G, et al. Platelet counts and platelet activation markers in obese subjects. Mediators Inflamm. 2008; 2008: 1-6, CrossRef.

Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost 2007; 5: 132-42, CrossRef.

Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost. 2001; 85: 958-65, PMID.

Monasterioa J, Bermúdeza P, Quirogaa D, Franciscoa E, Menesesa B, Montanerb J. Plasma thrombin-activatable fibrinolytic inhibitor (TAFI) among healthy subjects and patients with vascular diseases: A validation study. Pathophysiol Haemost Thromb. 2004; 33: 382-6, CrossRef.


Copyright (c) 2012 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Indexed by:






The Prodia Education and Research Institute